SPP1 + Venous Endothelial Cells and CRABP2 + Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.23936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Yueze Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medic…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Endothelial Cells, Osteopontin, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy; however, no validated treatments are currently available. Clinically, the tumor position, head and uncinate process (HU), or body and tail (BT) of the pancreas are vital for surgical strategies; however, fundamental research has seldom revealed the heterogeneous tumor microenvironment (TME) among different types of PDAC. Here, we applied multicohort single‐cell and spatial RNA‐seq methods together with patient‐derived organoid models to reveal the TME heterogeneity between HU and BT PDAC. Osteopontin, encoded by SPP1 , is secreted by vessel endothelial cells in BT PDAC and is associated with increased tumor burden. The number of tumor cells marked by CRABP2 was lower in BT PDAC and was identified as a prognostic marker of overall survival, as well as CD8 + T‐cell infiltration. The expression of CRABP2 was also validated to be downregulated in BT PDAC in patient‐derived organoid models. Overall, we profiled the heterogeneous PDAC TME between HU and BT PDAC, which could provide novel insight into the relationships between clinical characteristics and TME molecular research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Surgery Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 4+4 Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical…
- Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Yifan Fu, Wenhao Luo
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Fu, Y., Liu, T., Wang, J., Zhang, Z., Shi, Y., Cao, Z., Yang, G., Chen, H., Luo, W., Tao, J., Wang, Y., Weng, G., Zhang, M., Ye, L., Xiao, J., Qiu, J., Zhang, T., & Huang, H. (2025). SPP1 + Venous Endothelial Cells and CRABP2 + Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23936
Vancouver
Liu Y, Fu Y, Liu T, Wang J, Zhang Z, Shi Y, et al. SPP1 + Venous Endothelial Cells and CRABP2 + Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23936
BibTeX
@article{Liu2025,
author = {Liu, Yueze and Fu, Yifan and Liu, Tao and Wang, Jun and Zhang, Zeyu and Shi, Yanan and Cao, Zhe and Yang, Gang and Chen, Hao and Luo, Wenhao and Tao, Jinxin and Wang, Yuanyang and Weng, Guihu and Zhang, Menggang and Ye, Liyuan and Xiao, Jianchun and Qiu, Jiangdong and Zhang, Taiping and Huang, Hua},
title = {SPP1 + Venous Endothelial Cells and CRABP2 + Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.23936}
}
EUVIMED